Background {#Sec1}
==========

Fragile X Syndrome (FXS) is a common monogenic syndrome associated with intellectual disability (ID) and autism features, caused by a trinucleotide CGG expansion (≥ 200 repeats), termed full mutation (FM) \[[@CR1]\]. FM alleles are usually associated with increased methylation of the *FMR1* promoter extending into *FMR1* intron 1, and decreased transcription of *FMR1* and loss of its product, fragile X mental retardation protein (FMRP) (reviewed in \[[@CR2]\]). FMRP is essential for normal neurodevelopment, with its loss associated with FXS phenotypes including learning and memory deficits, intellectual functioning, behavioural problems, and autism features \[[@CR3]\].

*FMR1* alleles with smaller size CGG expansion (55--199 repeats) have been termed premutation (PM). These PM alleles have been reported to have an unmethylated *FMR1* promoter and abnormally increased levels of *FMR1* mRNA \[[@CR4], [@CR5]\]. This increased transcription has been postulated to cause "RNA gain of function" toxicity that has been associated with late onset disorders in a proportion of PM carriers \[[@CR4], [@CR5]\]. Other potential pathogenic mechanisms described in PM-related disorders include marginally decreased FMRP, expanded repeat associated non-AUG translation, as well as increased transcription of *ASFMR1*/*FMR4* originating from the same locus as *FMR1*, but in the anti-sense direction (reviewed in \[[@CR2]\]).

Approximately 12--41% of males with FXS have been reported to have CGG size and/or methylation mosaicism \[[@CR6], [@CR7]\]. CGG size mosaicism occurs when some cells contain alleles of different sizes in the same individual. The most common mosaicism reported in FXS \[[@CR6], [@CR7]\] is unmethylated PM and FM alleles in some cells and methylated FM alleles in others, defined in this study as PM/FM mosaicism. Mosaicism can also occur in the absence of PM alleles, where some cells have methylated FM alleles that do not express mRNA and others that have unmethylated and transcribed FM alleles.

The previous prevalence estimates of mosaicism in FXS (12--41%) are likely to be under-estimated, as previous studies have defined mosaicism using methylation-sensitive Southern blot, a technique that cannot detect mosaic alleles if present in less than 20% of cells \[[@CR8]\]. Attenuated FXS phenotypes have been described in these cases, though significant variability is still observed \[[@CR9]\], and autistic features remain common \[[@CR10]\]. Several case reports have also indicated that individuals mosaic for unmethylated PM and FM alleles express *FMR1* mRNA from expanded PM and FM alleles, and have a fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype, based on clinical assessments and MRI features \[[@CR11]--[@CR13]\]; though associations with other FXS characteristics have not been explored in large samples of FXS individuals.

While there is a vast amount of literature that has explored the molecular mechanisms that underpin the specific behavioural phenotype of FXS (FM and PM/FM mosaic), these studies have predominantly focused on CGG sizing, FMRP in blood and DNA methylation analyses using Southern blot (reviewed in \[[@CR2]\]). Studies examining the associations between *FMR1* mRNA, level of mosaicism and the behavioural phenotypes in FXS males and females are lacking. Moreover, the real-time PCR method most commonly used in previous studies of *FMR1* mRNA "toxicity" normalised *FMR1* mRNA to β-glucuronidase as a single internal control gene, which is not stably expressed in blood, and has been reported to be itself associated with PM-related phenotypes \[[@CR14], [@CR15]\].

This is the first study aimed at determining if phenotypic differences exist between FM males with complete and incomplete *FMR1* mRNA silencing in peripheral blood mononuclear cells (PBMCs). The study also explored relationships between the levels of *FMR1* mRNA (if not completely silenced) in PBMCs and severity of intellectual functioning and autism features using improved methodologies for more accurate quantification of mRNA in *FMR1*related disorders \[[@CR15], [@CR16]\]. Moreover, with the advent of calibrated severity scores (CSS) for both the social affect and repetitive and restricted behaviour domains of the Autism Diagnostic Observation Schedule (ADOS) \[[@CR17]\], this study used a more detailed approach to assess autism features.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

This study comprised a large international cohort of 98 (70.4% male) individuals with FXS recruited in Australia and Chile. Male participants (*n* = 69; 79.7% FM-only) were aged between 1.89 and 43.17 while female (*n* = 29; 75.9% FM-only) participants were aged between 1.71 and 32.52 years. A control group of 14 females (aged 22 to 54 years) was also included for reference ranges of *FMR1* mRNA levels. These individuals had confirmed normal size alleles (CGG \< 45), and were recruited as part of previous studies \[[@CR18]\].

All participants had undergone fragile X genetic testing prior to recruitment using CGG PCR sizing and Southern blot analysis, as previously described \[[@CR19], [@CR20]\]. Individuals were excluded from the study if they had any other genetic conditions of known clinical significance, if they had any significant medical conditions (e.g. stroke, head trauma) and/or if they had inadequately controlled seizures.

Sample processing {#Sec4}
-----------------

Five millilitre venous blood samples were collected in EDTA tubes at the time of assessment. PBMC isolation was performed using Ficoll gradient separation, as previously described \[[@CR21]\], and RNA extracted using RNeasy kit as per manufacturer's instructions (Qiagen, Germany).

*FMR1* mRNA analysis {#Sec5}
--------------------

Complementary DNA (cDNA) strand synthesis was then performed on 10 ng of RNA for each sample using the High Capacity cDNA Reverse Transcription kit (Thermo Fisher scientific, Global). ViiA 7 Real-Time PCR System (Life Technologies, Global) was then used for *FMR1* mRNA analysis using the reverse transcription real-time PCR. The relative standard curve method was utilised for *FMR1* 5′ and 3′ mRNA quantification normalised to mRNA of two internal control genes (*EIF4A2* and *SDHA*), as previously described \[[@CR14], [@CR15]\], with mean of three technical replicates used to represent relative *FMR1* mRNA levels for each sample in normalised arbitrary units (a.u.).

Intellectual functioning {#Sec6}
------------------------

Depending on age and country, participants were assessed with one of the following standardised assessments: the Mullen Scales of Early Learning (MSEL; Australian children \< 3 years) \[[@CR22]\], the Wechsler Preschool and Primary Scale of Intelligence-3rd Edition (WPPSI-III; children aged 3 years to 6 years, 11 months) \[[@CR23], [@CR24]\], the Wechsler Intelligence Scale for Children-4th Edition Australian (WISC-IV; Australian children aged 7 years to 16 years, 11 months) \[[@CR25]\]/Wechsler Intelligence Scale for Children-3rd Edition Spanish (WISC-III; Chilean children aged 7 years to 16 years, 11 months) \[[@CR26]\] or the Wechsler Adult Intelligence Scale-4th Edition Australian and Chilean editions (WAIS-IV; individuals aged 17+ years) \[[@CR27], [@CR28]\]. To address the floor effect that is commonly observed for individuals with FXS on standard intellectual functioning assessments, corrected IQ scores (cFSIQ, cVIQ, cPIQ) were used \[[@CR29]\]. A limitation to this method in the current study is that the WISC-III (Chilean version) incorporates working memory (WM) and processing speed (PS) tasks in the verbal and perceptual reasoning indexes, and these types of tasks have previously been shown to be a relative deficit in the cognitive profiles of individuals with FXS \[[@CR30], [@CR31]\]. Moreover, while Verbal IQ (VIQ), Performance IQ (PIQ) and Full Scale IQ (FSIQ) (early learning composite as a proxy for FSIQ) scores can be derived from the MSEL \[[@CR32], [@CR33]\], the assessment is qualitatively different to that of the Wechsler scales. Therefore, in the supplementary materials, the analyses using (i) standard scores and (ii) corrected scores with participants assessed with the MSEL and WISC-III removed are presented.

Autism features {#Sec7}
---------------

The Autism Diagnostic Observation Schedule-2nd Edition (ADOS-2) \[[@CR34]\] was used to assess autism features. The ADOS-2 is a semi-structured assessment conducted by an unfamiliar adult to the individual being assessed. Separate Calibrated Severity Scores (CSS) based on the overall (ADOS CSS), social affect (SA CSS) and restricted and repetitive behaviour (RRB CSS) domains were also derived for each module \[[@CR17], [@CR35], [@CR36]\]. ADOS-2 assessments were conducted by research members who had undertaken ADOS-2 for research training and had demonstrated \> 80% coding reliability across all five modules.

Procedure {#Sec8}
---------

Participants attended an appointment for psychological assessment and venous blood collection. All procedures were approved by The Royal Children's Hospital and INTA Human Research Ethics Committees (HREC \#33066 and \#15, respectively). All parents/caregivers provided written informed consent and those who were deemed cognitively able also provided written informed consent.

Data analysis {#Sec9}
-------------

Summary statistics were presented by sample size and percentage for categorical variables and mean and standard deviation for continuous variables. Comparisons for the differences between sex for mean age and proportion of full mutation alleles only (FM-only) were carried out using a two-sample *t* test. Spearman's rank correlation was used to assess relationships between *FMR1* mRNA and age in males and females.

For intellectual functioning and autism features, regression methods were used to compare the difference between sex or allelic class, or relationship with *FMR1* mRNA, adjusted for the covariates of age, country, ADOS CSS for intellectual functioning and corrected full scale IQ (cFSIQ) for autism features where significant. The semi-parametric regression was employed with age as the non-parametric component and other covariates as parametric components because intellectual functioning scores had a non linear relationship with age. Otherwise, either least square or robust regression (to downweight the effect of outliers) were used if age was not associated with the outcome variable.

To further examine the impact of *FMR1* mRNA levels on phenotypic variables in the male cohort, the FM-only group was split based on the presence (*FMR1* mRNA a.u. \> 0) or absence (*FMR1* mRNA a.u. = 0) of *FMR1* mRNA in peripheral blood and comparisons were made between these two groups using semi-parametric regression for intellectual functioning scores and robust regression for ADOS scores. These same analyses were undertaken using only children and adolescents (\< 19 years) and pre-pubertal children (\< 13 years).

False discovery rate (FDR) was used to adjust for multiple testing. All analyses were carried out using commercial software Stata *version 15* (<http://www.stata.com>); *p* values were two-sided and a variable was considered significant if it was less than 0.05.

Results {#Sec10}
=======

Male and female participants did not differ significantly on age (males: Mean (*M*) = 13.38, Standard Deviation (*SD*) = 10.07; females: *M* = 10.87, *SD* = 8.71; *p* = 0.244). Allelic classification (FM-only versus PM/FM mosaic) also did not differ between males and females (*p* = 0.672).

Inter-group comparisons of intellectual functioning and autism features {#Sec11}
-----------------------------------------------------------------------

Comparisons of phenotypic variables between males and females (FM-only and PM/FM mosaics combined) showed that males had significantly lower intellectual functioning scores on all domains assessed (Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1), though the two groups did not differ on ADOS scores, after controlling for cFSIQ (Table [1](#Tab1){ref-type="table"}).Table 1Comparison between males and females on intellectual functioning (corrected) scores and autism featuresMalesFemales*pnM* ± *SDnM* ± *SD*Intellectual functioning^a^ cVIQ6642.5 ± 23.62973.1 ± 17.6\< *0*.*0001*\* cPIQ6742.7 ± 19.72966.9 ± 15.8\< *0*.*0001*\* cFSIQ6629.6 ± 24.22965.9 ± 17.2\< *0*.*0001*\*Autism features^b^ ADOS CSS626.69 ± 2.00254.92 ± 2.360.573 SA CSS626.56 ± 2.19254.80 ± 2.250.814 RRB CSS627.37 ± 1.88256.76 ± 2.280.708^a^Semi-parametric regression adjusted for country, age and ADOS CSS^b^Robust regression adjusted for country and cFSIQ; \**p* value remained \< 0.05 after adjustment for multiple testing

Inter-group comparisons of *FMR1* mRNA levels {#Sec12}
---------------------------------------------

FM-only males had significantly lower *FMR1* mRNA compared to FM-only females and PM/FM mosaic males (Fig. [1](#Fig1){ref-type="fig"}). The two FXS female groups did not significantly differ on *FMR1* mRNA levels and neither did the male and female PM/FM mosaic groups (Fig. [1](#Fig1){ref-type="fig"}). No females with FXS and no PM/FM mosaic males had completely silent *FMR1* mRNA (Females: 0.013--2.170 a.u.; PM/FM mosaic males: 0.354--2.260 a.u.), while 40% of FM-only males had complete silencing of *FMR1* mRNA (range 0.0--2.514 a.u.).Fig. 1Intergroup comparisons of *FMR1* mRNA levels in blood of males and females with FXS and controls (CGG \< 45). *p* values for the intergroup comparisons were derived using the Wilcoxon rank-sum test. \**p* \< 0.05 compared to controls; \*\*\**p* \< 0.00001 compared to controls

Stratification based on presence or absence of complete *FMR1* mRNA silencing in FM-only males and associations with intellectual functioning and autistic features {#Sec13}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comparisons between FM-only males with complete versus incomplete *FMR1* mRNA silencing demonstrated that FM-only males with incomplete *FMR1* mRNA silencing had significantly elevated ADOS CSS compared to FM-only males with complete *FMR1* mRNA silencing, for participants less than 19 years of age (Fig. [2](#Fig2){ref-type="fig"}b; *p* = 0.0016), and this difference remained significant after adjusting for country and cFSIQ and FDR, as did the difference on SA CSS (Table [2](#Tab2){ref-type="table"}). When only children (\< 13 years), or when adults were also included (\< 37 years of age), ADOS CSS were also significantly higher in the incomplete silencing group (Fig. [2](#Fig2){ref-type="fig"}a,c). These differences were significant after adjusting for cFSIQ and country, but did not survive FDR (Table [2](#Tab2){ref-type="table"}).Fig. 2Autistic features and intellectual functioning in FM only males stratified based on presence or absence of *FMR1* mRNA in blood. Intergroup comparisons of autistic features in FM only males \< 13 years of age (**a**), \< 19 years of age (**b**), \< 37 years of age (**c**) and intellectual functioning in FM only males \< 37 years of age (**d**), with broken lines representing CSS scores ≥ 4 (ASD cut-off previously reported for ADOS-2 \[[@CR37]\]). *p* values for the intergroup comparisons were derived using the Wilcoxon rank-sum test. Black, dark and light grey dots represent the same participants between all four figures with FSIQ ≥ 70Table 2Comparison between FM-only males with complete and incomplete *FMR1* mRNA silencing on intellectual functioning (corrected) scores and autism featuresFM-only with incomplete *FMR1* mRNA silencingFM-only with complete *FMR1* mRNA silencing*pnMSDnMSD*Intellectual Functioning^a^ cVIQ3337.026.92141.520.40.196 cPIQ3336.820.62144.419.50.980 cFSIQ3322.924.32128.423.20.497Autism features (whole sample)^b^ ADOS CSS307.231.74205.902.29*0*.*041* SA CSS307.072.00205.952.56*0*.*035* RRB CSS307.731.57206.702.300.202Autism features (\< 19 years)^b^ ADOS CSS247.291.85165.312.09*0*.*011*\* SA CSS247.082.19165.502.61*0*.*029*\* RRB CSS247.831.66166.502.420.171Autism features (\< 13 years)^b^ ADOS CSS197.161.92135.312.18*0*.*050* SA CSS197.112.21135.152.58*0*.*047* RRB CSS197.681.77136.772.450.647^a^Semi-parametric regression adjusted for country, ADOS CSS and age^b^Robust regression adjusted for country and cFSIQ; \**p* value remained \< 0.05 after adjustment for multiple testingItalic values indicate significance prior to adjustment for multiple testing

Moreover, only 3% of FM-only males with incomplete *FMR1* mRNA silencing had an ADOS CSS that was less than 4, as compared to 20% of FM-only males with complete *FMR1* silencing (Fig. [2](#Fig2){ref-type="fig"}c); similar proportions of FM-only males with ADOS CSS below 4 were found when using children and adolescents (Fig. [2](#Fig2){ref-type="fig"}b) and children \< 13 years (Fig. [2](#Fig2){ref-type="fig"}a). A CSS of 4 or above is the cut-off previously used for classification for presence of autism spectrum disorder (ASD) \[[@CR37]\]. In contrast, the two FM-only male groups did not differ significantly on any of the intellectual functioning scores (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}d). No significant differences were also observed on intellectual functioning scores between the two FM-only groups when stratified by age groups (*p* \> 0.05; Additional file [1](#MOESM1){ref-type="media"}: Table S2).

Relationships between *FMR1* mRNA levels, age and phenotypes {#Sec14}
------------------------------------------------------------

*FMR1* mRNA levels were positively correlated with age in FXS females (*n* = 29, correlation (*r*~*s*~) = 0.642, *p* \< 0.001), but not in FXS males (*n* = 69, *r*~*s*~ = 0.157, *p* = 0.199; Fig. [3](#Fig3){ref-type="fig"}a, b). In males, regardless of allelic classification (FM-only and PM/FM mosaic), *FMR1* mRNA levels were significantly associated with corrected verbal IQ (cVIQ) and cFSIQ (Table [3](#Tab3){ref-type="table"}). *FMR1* mRNA levels were significantly associated with all standard intellectual functioning scores in males (Additional file [1](#MOESM1){ref-type="media"}: Table S3; Fig. [3](#Fig3){ref-type="fig"}c). However, no associations were observed between *FMR1* mRNA and autistic features in the combined male FXS cohort (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}e). When the WISC-III (Chile) and MSEL were removed, cVIQ and cFSIQ remained significantly associated with *FMR1* mRNA levels in males (Additional file [1](#MOESM1){ref-type="media"}: Table S4).Fig. 3Relationships between age and phenotype severity with *FMR1* mRNA levels in blood of males and females with FXS. Relationships between *FMR1* mRNA levels in blood and age in (**a**) males and (**b**) females with FXS. Relationships between *FMR1* mRNA levels in blood and intellectual functioning in (**c**) FXS males using robust regression and (**d**) FXS females using ordinary regression (also see Table [3](#Tab3){ref-type="table"}). Relationships between *FMR1* mRNA levels in blood and autistic features in (**e**) FXS males using robust regression adjusted for country and cFSIQ and (**f**) FXS females using robust regression adjusted for cFSIQ (also see Table [3](#Tab3){ref-type="table"}). Solid dots represent FM-only, while open dots represent PM/FM mosaicsTable 3Relationship between intellectual functioning (corrected) scores and autism features, with *FMR1* mRNA levels in males and femalesMalesFemales*nβ ± sepnβ ± sep*Intellectual Functioning (corrected)^a^ cVIQ669.09 *±* 3.90*0*.*023*\*2810.6 *±* 6.180.087 cPIQ678.71 *±* 4.770.072282.85 *±* 4.680.543 cFSIQ669.46 *±* 4.24*0*.*029*\*285.32 *±* 4.500.237Autism features^b^ ADOS CSS590.12 *±* 0.250.62725− 8.00 *±* 0.690.249 SA CSS590.52 *±* 0.330.11825− 0.78 *±* 0.710.270 RRB CSS59− 0.13 *±* 0.250.612250.22 *±* 0.690.753^a^Semi-parametric regression adjusted for country, ADOS CSS and age for males and robust regression adjusted for ADOS CSS for females^b^Robust regression adjusted for country and corrected FSIQ for males and only corrected FSIQ for females; *β* = estimated regression coefficient; se = standard error. \**p* value remained \< 0.05 after adjustment for multiple testingItalic values indicate significance prior to adjustment for multiple testing

In contrast, *FMR1* mRNA levels were not associated with any of the corrected intellectual functioning scores or ADOS CSS in FXS females (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}d, f). Similarly, no associations were observed between *FMR1* mRNA levels and standard intellectual functioning scores (Additional file [1](#MOESM1){ref-type="media"}: Table S3) or corrected intellectual functioning scores when the WISC-III (Chile) and MSEL were removed (Additional file [1](#MOESM1){ref-type="media"}: Table S4) in females with FXS.

Associations between *FMR1* mRNA levels and intellectual functioning and autistic features in FM-only males with incomplete *FMR1* mRNA silencing and PM/FM mosaic males {#Sec15}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant associations were observed with cVIQ, corrected performance IQ (cPIQ) and cFSIQ (Table [4](#Tab4){ref-type="table"}) with *FMR1* mRNA levels in the PM/FM mosaic group. VIQ, PIQ and FSIQ were associated with *FMR1* mRNA levels in both FM-only males with incomplete silencing and PM/FM mosaic males (Additional file [1](#MOESM1){ref-type="media"}: Table S5). The association between *FMR1* mRNA levels and standard FSIQ in the combined cohort was predominantly due to the associations being observed in the PM/FM mosaic males, and not the FM-only male group (Fig. [3](#Fig3){ref-type="fig"}c). In contrast, no significant associations were found between *FMR1* mRNA levels and autistic features in these two groups of males (Table [4](#Tab4){ref-type="table"}).Table 4Relationship between intellectual functioning (corrected) scores, and autism features, with *FMR1* mRNA levels in FM-only males with incomplete *FMR1* mRNA silencing and PM/FM mosaic malesFM-only with incomplete *FMR1* mRNA silencingPM/FM mosaic*nβ ± sepnβ ± sep*Intellectual functioning cVIQ3214.7 *±* 38.70.7051213.6 *±* 4.52*0*.*003*\* cPIQ3213.5 *±* 25.30.5941314.8 *±* 3.77\< *0*.*001*\* cFSIQ326.75 *±* 27.60.807129.62 *±* 4.28*0*.*025*\*Autism features ADOS CSS29− 0.78 *±* 0.770.31012− 0.85 *±* 0.870.331 SA CSS29− 0.60 *±* 0.980.53812− 0.79 *±* 1.040.448 RRB CSS29− 0.92 *±* 0.960.33812− 1.16 *±* 0.650.074Robust regression was used to conduct analysis, without adjustment for any covariate. \**p* value remained \< 0.05 after adjustment for multiple testingItalic values indicate significance prior to adjustment for multiple testing

Discussion {#Sec16}
==========

This is the first study to demonstrate that the presence of incomplete *FMR1* mRNA silencing in blood is significantly associated with more severe autism features (predominantly social communication difficulties) in FM-only males. Specifically, FM-only males with incomplete *FMR1* mRNA silencing had elevated ADOS CSS and SA CSS compared to those with complete *FMR1* mRNA silencing, though these associations were predominantly observed in the paediatric cohort (\< 19 years). Moreover, 21% more of the FM-only male group with incomplete silencing aged \< 19 years met the ADOS-2 criteria for ASD (CSS ≥ 4), as compared to FM-only males with complete *FMR1* mRNA silencing (\< 19 years). In contrast, there were no differences on intellectual functioning scores (e.g. FSIQ), when stratified based on the presence of FM *FMR1* mRNA in blood. These findings suggest that the link between presence of potentially toxic FM mRNA and autism features may be stronger during earlier development and adolescence before neurodegenerative processes begin in adulthood that may confound the analysis. The loss of significant differences post FDR in the male children aged under 13 years may be an artefact of the smaller sample size or indeed that adolescence is a critical time-point.

Intellectual disability and autistic features, while linked, are variable in FXS, which may be explained by contribution from two different, but overlapping, patho-mechanisms: (i) namely silencing of mRNA resulting in loss of FMRP; and (ii) overexpression of toxic expanded mRNA by active unmethylated FM alleles. This is particularly important in light of the significant research performed to date aiming to re-activate methylated FM alleles as a potential therapy performed in various cell line models \[[@CR38]--[@CR42]\]. This may also explain, in part, why preclinical studies in *FMR1* knockout (KO) animal models, trialling drugs that correct pathways dysregulated due to complete loss of *FMR1*, were largely unsuccessful in human trials \[[@CR43]\]. The *FMR1* FM mRNA toxicity mechanism does not apply to *FMR1* KO animal models, while it may have significant implications for the behavioural phenotype in patients affected with FXS, especially because behavioural phenotypes were targeted by most primary outcome measures in the recent clinical trials \[[@CR43], [@CR44]\]. If FM mRNA is indeed expressed in the majority of FXS males, consistent with the results for 60% of FM-only males in this study, even at low levels, reactivation of large expanded alleles may not be a viable in vivo treatment strategy. While increase in FM mRNA and presence of FMRP may lead to improvements in intellectual functioning in males with unmethylated FM alleles, issues associated with RNA toxicity may be exacerbated. Perhaps excision of FM all together, as previously described \[[@CR45], [@CR46]\], or treatment of downstream pathways targeting both FM RNA toxicity as well as FMRP deficiency is a better option.

Since FXTAS is believed to be associated with RNA toxicity, and previous adult patients with FXS and FXTAS features had low bulk (average levels between cells) *FMR1* mRNA levels \[[@CR11]--[@CR13]\] similar to those observed in this study, our data suggests that expression of expanded FM alleles may be toxic, independent of high or low bulk mRNA levels, as compared to the control range. The stratification based on the presence or absence of FM mRNA reported in this study also suggests that potentially toxic mRNA expressed from FM alleles may be implicated in the pathogenesis of autism, though further studies in larger FXS cohorts and functional studies are required to confirm these findings.

It is notable that the RNA toxicity hypotheses cannot be explored in the current KO mouse models of FXS and animal models do not fully recapitulate the behavioural phenotype of FXS. An alternative approach to explore in vivo functional links between mRNA toxicity, the type of toxicity (e.g. including toxic gain of function, as well as sense and anti-sense Repeat Associated non-ATG translation \[Reviewed in Kraan et al. \[[@CR2]\]\]) and FMRP deficiency would be to use post-mortem brain tissues from FXS males, who had previously undergone formal assessments of intellectual functioning and autism.

Three cases in the present study (highlighted in Fig. [2](#Fig2){ref-type="fig"}) further demonstrate the complexity of disentangling the relationships between autism and ID in FXS. Two cases in the FM-only group with complete *FMR1* mRNA silencing had FSIQ scores of 71 and while one of these cases had moderate autism features (ADOS CSS = 6), the other had minimal autism features (ADOS CSS = 1); these cases are represented by the dark grey and black dots in Fig. [2](#Fig2){ref-type="fig"}, respectively. The third case, from the incomplete silencing group, had a FSIQ of 70 and minimal autism features (ADOS CSS = 2). This latter participant had an *FMR1* mRNA level of 0.091 a.u. and is represented by the light grey dot in Fig. [2](#Fig2){ref-type="fig"}. This low level of *FMR1* expression in these three higher functioning FXS cases suggests that blood may have limited representation of *FMR1* mRNA levels in the brain in a proportion of cases; though other factors may also contribute. Increasing age has been associated with increasing autism symptoms in males with FXS \[[@CR47], [@CR48]\], while a widening gap between FXS and typically developing individuals has been observed for intellectual functioning measures \[[@CR31]\]. Of note is that these three cases were aged 3.92, 5.49 and 2.21 years, respectively.

Despite the significant differences observed between the two complete and incomplete *FMR1* mRNA FM-only groups on ADOS CSS, the overlap between autism features and anxiety, particularly social anxiety, cannot be ignored. It has been suggested that elevated symptoms of ASD in FXS can be attributed to the social anxiety experienced by these individuals \[[@CR49], [@CR50]\]. Roberts and colleagues \[[@CR49]\] demonstrated significant associations between a composite social anxiety measure (derived from the Social Avoidance Scale \[[@CR51], [@CR52]\], Anxiety Depression and Mood Scale: Avoidance subscale \[[@CR53]\] and the Child Behavior Checklist-Anxiety problems scale \[[@CR54]\]) and ADOS CSS in a sample of 59 adolescent and adult FXS males (15--23 years), highlighting the significant overlap between ASD features and social anxiety in FXS. Thus, it is possible that expression of *FMR1* mRNA is associated with social anxiety rather than ASD features, or a combination of overlapping symptoms between the two constructs. As concluded by Roberts and colleagues \[[@CR49]\], the relationship between social anxiety and ADOS-2 scores is likely bi-directional. Future research aiming to disentangle autism features and social anxiety and their relationship with molecular mechanisms, such as *FMR1* mRNA, is warranted, as this may have implications for treatments that target these specific behaviours.

If confirmed in future studies that FM mRNA is associated with autism features, then stratification of FM males based on the presence or absence of mRNA may be a complimentary approach to define the presence of mosaicism in FXS males, especially for clinical trials where primary outcome measures target behavioural issues. Such patient stratification has previously been shown to result in different treatment outcomes \[[@CR55]\]. In the placebo controlled trial of AFQ056 (mavoglurant), a mGluR5 antagonist targeting FMRP deficiency, in 30 males with FXS, no significant effects of treatment were observed on Aberrant Behavior Checklist-Community (ABC-C) \[[@CR56]\] total scores when males with complete and incomplete *FMR1* mRNA silencing were analysed as one combined group. However, significant improvements in ABC-C scores were observed in all patients who had complete absence of *FMR1* mRNA (*n* = 7), after treatment compared to placebo \[[@CR55]\].

Only one study has specifically explored the relationship between *FMR1* mRNA levels in blood and autism features in males with FXS (*n* = 63; 38% PM/FM mosaic), and provided appropriate statistical analyses at group level \[[@CR3]\]. This study demonstrated that none of the molecular markers analysed, including *FMR1* mRNA in blood, were associated with communication-social total scores of the ADOS or with the overall autism rating. Interestingly, the male with the most elevated mRNA level in that cohort had autism, prompting the researchers to suggest further research in this area \[[@CR3]\]. The study, however, did not dichotomize FXS participants based on the presence of complete or incomplete *FMR1* silencing, and did not report on whether this stratification strategy resulted in associations with elevated autism features in FXS, as reported in this study.

Moreover, the Harris et al. \[[@CR3]\], and most of the studies that followed examined *FMR1* mRNA "toxicity", using the real-time PCR method targeting a single 5′ region of *FMR1* mRNA \[[@CR57]\]. The levels detected by this single assay were then normalised to β-glucuronidase as a single internal control gene in most of these studies, described in Kraan et al. \[[@CR14]\]. Importantly, Kraan et al. \[[@CR14]\] reported that β-glucuronidase expression was not stably expressed in blood, and has been itself associated with PM-related phenotypes \[[@CR14], [@CR15]\]. In contrast, this study used a real-time PCR method that targeted two conserved regions at both 5′ and 3′ends of *FMR1* mRNA, normalising the target mRNA levels to multiple internal control genes \[[@CR15], [@CR16]\]. This was an improved methodology that allowed for a more accurate quantification of mRNA because targeting mRNA at both ends by this approach controls for technical variability resulting from loss of signal due to mRNA degradation at either end of the mRNA \[[@CR58]\]. This approach at the same time normalised the mRNA levels detected by the target assays to multiple stably expressed control genes, that have not been previously associated with PM or any other *FMR1* related phenotypes \[[@CR15], [@CR16]\].

Using this highly quantitative method in the current study, significant associations were also observed between *FMR1* mRNA levels in blood and intellectual functioning scores in FXS males. The most consistent findings were poorer verbal abilities and overall intellectual functioning associated with lower *FMR1* mRNA. Nonetheless, these associations were primarily driven by the PM/FM mosaic cohort. When examining the associations between *FMR1* mRNA and corrected intellectual functioning in the FM-only male group with incomplete *FMR1* mRNA silencing, no significant associations were found, while associations were consistently observed in the PM/FM mosaic male group.

As expected, females with FXS had significantly higher levels of *FMR1* mRNA and less severe phenotype, than males. However, in females, there were no significant associations between *FMR1* mRNA and intellectual functioning and autistic features. In contrast, there was a highly significant association between mRNA levels and age, in females but not males, whereby older age was associated with higher *FMR1* mRNA levels. This is consistent with previous literature examining *FMR1* promoter methylation in FXS, where methylation decreased with age in females (but not males) \[[@CR59]\]. This supports the previous hypothesis that in blood of FM females, there is likely positive selection for cells with the normal CGG size allele on the active X over time, thus leading to increased *FMR1* expression with age.

Interestingly, this increase in mRNA with age does not appear to be associated with improvements in the cognitive and behavioural phenotypes in the females included in this study. This lack of association in females, but not males, may be explained by a significantly smaller sample size of FXS females as compared to males, in this study or potentially because expression in blood at a single time-point (where there is a high turnover of cells) may not reflect expression in the brain, where cell turnover is not as high. Moreover, the cross-sectional analysis of this data does not allow for observation of change over time, including the interplay of biological drivers (e.g. *FMR1* mRNA), environmental factors and the phenotype. Thus, longitudinal studies are required to further explore these findings.

Considering that FM *FMR1* mRNA is expressed in most FXS males, future studies should also explore expression of antisense transcripts including *ASFMR1* and *FMR4* previously reported to be over-expressed in PM-related disorders \[[@CR21]\]. Analysis of expanded CGG repeat associated sense and antisense non-AUG translation, previously associated with PM-related disorders as an alternative mechanism to RNA toxicity, and relationships between these variables and FXS phenotypes, would also be of great interest in future FXS studies.

Limitations {#Sec17}
-----------

Notwithstanding its strengths, an important limitation of this study is that the study reports *FMR1* mRNA levels assuming that they correspond to protein (FMRP) levels, with the latter being the ultimate "top level" molecular factor in FXS. While this is a solid assumption for FM-only males with reported complete silencing, where FMRP could not be present with no mRNA to translate, for FM males with incomplete silencing, levels of *FMR1* mRNA may not reflect those of FMRP. Future studies should explore if stratification of FXS males based on the presence or absence of FMRP is concordant with the findings reported in this study using *FMR1* mRNA-based stratification.

Another limitation is that *FMR1* mRNA analysis performed using real-time PCR represents bulk mRNA levels. As previously suggested in studies examining *FMR1* mRNA toxicity in mosaic FXS cases with FXTAS phenotypes \[[@CR60], [@CR61]\], bulk mRNA analysis averages out levels between cells that overexpress mRNA and cells that have mRNA completely silenced. This may mean that if there is a small number of cells expressing toxic/elevated FM *FMR1* mRNA, and the majority have mRNA completely silenced, the bulk mRNA result will be decreased total mRNA output. This may also explain the lack of associations observed between *FMR1* mRNA levels and autism features in the FM-only male group with incomplete silencing, while group differences on ADOS CSS when stratified based on the presence or absence of *FMR1* mRNA were present. Future studies should explore the utility of single-cell RNA sequencing to further detangle the *FMR1* silencing and FM mRNA toxicity mechanisms in FXS at a single cell level.

Another limitation of the current study is the small sample sizes for the PM/FM mosaic male and female cohorts, which limits the generalisability of the findings in these groups. The use of multiple assessment types for intellectual functioning is common in FXS; however, the MSEL is qualitatively different to the Wechsler scales and the WISC-III (Chilean edition) incorporates PS and WM tasks in the calculation of VIQ and PIQ, which may impact scores. Nonetheless, when those individuals who were assessed with these measures were removed from the analyses, similar results were observed. The use of the Stanford Binet Intelligence Scales-Fifth edition \[[@CR62]\] may be a more suitable measure in future studies where wide age ranges can be used. Lastly, only female control data is included in this study for reference ranges of *FMR1* mRNA; however, these levels overlap with age-matched males that have previously been reported elsewhere \[[@CR63]\].

Future studies should aim to expand upon and replicate the findings of the current study by (i) recruitment of larger independent cohorts, including increasing the sample size within each age bracket; (ii) undertaking longitudinal studies that examine developmental trajectories, particularly in the transition from childhood to adolescence and then again in the transition from adolescence to adulthood; (iii) incorporate a comprehensive multi-disciplinary assessment of ASD based on DSM-5 criteria to determine whether similar findings are observed for those with a comorbid clinical diagnosis of ASD; (iv) including a measure of social anxiety to tease apart autism features and anxiety; and (v) include other molecular markers such as FMRP. Such research will aid in understanding how molecular mechanisms (e.g. *FMR1* mRNA and FMRP) relate to specific clinical features of FXS across the lifespan.

Conclusion {#Sec18}
==========

In summary, this study characterised a large international FXS cohort, demonstrating that presence of *FMR1* transcription in FM-only males is common (present in 60% of FM-only males), and is associated with more severe autism features, including social communication difficulties, but not intellectual functioning (reflected by FSIQ). On the one hand, incomplete silencing of *FMR1* was associated with elevated autistic features as measured by ADOS-2 CSS, with 21% more of the 18 and under FM-only group expressing FM *FMR1* mRNA meeting the ADOS-2 criteria for ASD (CSS ≥ 4), as compared to FM-only males with completely silenced *FMR1*. On the other hand, decreased levels of *FMR1* mRNA were associated with decreased intellectual functioning in FXS males, with the relationships primarily driven by variability in the PM/FM mosaic subgroup. These novel findings, if confirmed by future independent studies, indicate that silencing of mRNA resulting in loss of FMRP, and overexpression of toxic expanded *FMR1* FM mRNA, occur together in the same individuals, for most FXS males. We postulate that the two reciprocal mechanisms may contribute to different, but overlapping aspects of FXS, namely intellectual disability and autism phenotype. This may have implications for (i) patient stratification in clinical trials and the outcome measures used in stratified subgroups; (ii) design of treatment strategies aiming to re-activate *FMR1* in FXS, which may result in production of harmful FM mRNA by a small proportion of cells; and (iii) preclinical trials targeting downstream pathways to both FM RNA toxicity as well as FMRP deficiency, as opposed to widely used, FXS KO models, where FM RNA toxicity cannot be studied.
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ADOS CSS

:   Overall ADOS-2 Calibrated Severity Score

ADOS

:   Autism Diagnostic Observation Schedule

ADOS-2

:   Autism Diagnostic Observation Schedule-2nd Edition

ASD

:   Autism spectrum disorder

cFSIQ

:   Corrected full scale IQ

cPIQ

:   Corrected performance IQ

CSS

:   Calibrated severity score

cVIQ

:   Corrected verbal IQ

FDR

:   False discovery rate

FM

:   Full mutation

FM-only

:   Full mutation alleles only

FMRP

:   Fragile X mental retardation protein

FSIQ

:   Full Scale IQ

FXS

:   Fragile X syndrome

KO

:   Knockout

MSEL

:   Mullen Scales of Early Learning

PIQ

:   Performance IQ

PM

:   Premutation

PM/FM

:   Premutation/Full mutation mosaic

RRB CSS

:   Repetitive and Restricted Behaviour Calibrated Severity Scores

SA CSS

:   Social Affect Calibrated Severity Scores

VIQ

:   Verbal IQ

WAIS-IV

:   Wechsler Adult Intelligence Scale-Fourth Edition

WISC-III

:   Wechsler Intelligence Scale for Children-Third Edition

WISC-IV

:   Wechsler Intelligence Scale for Children-Fourth Edition

WPPSI-III

:   Wechsler Preschool and Primary Scale of Intelligence-Third Edition
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